PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer

By Peddi Parvin   Hurvitz Sara  

Journal of Neuro-Oncology, Vol. 117, Iss. 1, 2014-03 ,pp. : 7-13

Springer Publishing Company

Access to resources Recommend Favorite

Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 1, 2010-01 ,pp. : 29-57

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 16, Iss. 1, 2016-01 ,pp. : 29-37

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical implications of Girdin and PI3K protein expression in breast cancer

By          

Oncology Letters, Vol. 5, Iss. 5, 2013-01 ,pp. : 1549-1553

Spandidos Publications

Access to resources Recommend Favorite

Differential sensitivities of trastuzumab (Herceptin^®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

By Chan Carmel   Metz Marianne   Kane Susan  

Breast Cancer Research and Treatment, Vol. 91, Iss. 2, 2005-05 ,pp. : 187-201

Springer Publishing Company

Access to resources Recommend Favorite